Cystatin C (CYSC) antibody and antigen (Recombinant protein)

 Download 

Product information

Size： 1mg | 10mg | 100mg

Catalog No.	Description	US $ Price (per mg)	First Order Discount	First Order Discount Price
GMP-h-CYSC-Ag01	Recombinant human CST3/CYSC Protein	3090
GMP-h-CYSC-Ab01	Anti-human CST3/CYSC mouse monoclonal antibody (mAb)	1953	20%	1562.4
GMP-h-CYSC-Ab02	Anti-human CST3/CYSC mouse monoclonal antibody (mAb)	1953	20%	1562.4
GMP-h-CYSC-Ab03	Anti-human CST3/CYSC human monoclonal antibody (mAb)	1953	20%	1562.4
GMP-h-CYSC-Ab04	Anti-human CST3/CYSC human monoclonal antibody (mAb)	1953	20%	1562.4

Shipping Costs: $360–$760
Antibodies: $360 Antigens: $760 (Elevated cost due to antigen heterogeneity, post-translational modifications, structural complexity, and specialized handling.)

Product Description

Cat No. of Products	GMP-h-CYSC-Ag01
Product Name	Recombinant human CST3/CYSC Protein
Target/Biomarker	Cystatin C (CYSC)
Alias of Target/Biomarker	ARMD11, HEL-S-2
Expression platform	mammalian
Isotypes	Recombinant Antigen
Bioactivity validation	Cystatin C (CYSC) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in CYSC level test of Kidney function (renal damages) (kidney function (renal damages)) and related syndrome evaluation.
Tag	His
Products description	Recombinant human CST3/CYSC Protein was expressed in mammalian expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-h-CYSC-Ab01, GMP-h-CYSC-Ab02
Product Name	Anti-human CST3/CYSC mouse monoclonal antibody (mAb)
Target/Biomarker	Cystatin C (CYSC)
Alias of Target/Biomarker	ARMD11, HEL-S-2
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Cystatin C (CYSC) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in CYSC level test of Kidney function (renal damages) (kidney function (renal damages)) and related syndrome evaluation.
Tag	mFc
Products description	Anti-human CST3/CYSC mouse monoclonal antibody (mAb) was expressed in CHO expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-h-CYSC-Ab03, GMP-h-CYSC-Ab04
Product Name	Anti-human CST3/CYSC human monoclonal antibody (mAb)
Target/Biomarker	Cystatin C (CYSC)
Alias of Target/Biomarker	ARMD11, HEL-S-2
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Cystatin C (CYSC) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in CYSC level test of Kidney function (renal damages) (kidney function (renal damages)) and related syndrome evaluation.
Tag	hFc
Products description	Anti-human CST3/CYSC human monoclonal antibody (mAb) was expressed in CHO expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

Cystatin C (CysC) is a relatively small protein that is produced throughout the body by all cells that contain a nucleus and is found in a variety of body fluids, including the blood. It is produced, filtered from the blood by the kidneys, and broken down at a constant rate. This test measures the amount of cystatin C in blood to help evaluate kidney function. Cystatin C (CysC) is filtered out of the blood by the glomeruli, clusters of tiny blood vessels in the kidneys that allow water, dissolved substances, and wastes to pass through their walls while retaining blood cells and larger proteins. What passes through the walls of the glomeruli forms a filtrate fluid. From this fluid, the kidneys reabsorb cystatin C, glucose, and other substances. The remaining fluid and wastes are carried to the bladder and excreted as urine. The reabsorbed cystatin C is then broken down and is not returned to the blood. The rate at which the fluid is filtered is called the glomerular filtration rate (GFR). A decline in kidney function leads to decreases in the GFR and to increases in cystatin C and other measures of kidney function, such as creatinine and urea in the blood. The increases in these levels occur because the kidneys are not able to properly filter the blood at a normal rate, causing their accumulation in the blood. On the other hand, improvement in kidney function is expected to lead to increases in GFR, which would cause cystatin C, creatinine, and urea to decline as a result of the kidneys being able to effectively clear them from the blood. When the kidneys are functioning normally, concentrations of cystatin C in the blood are stable. However, as kidney function deteriorates, the concentrations begin to rise. This increase in cystatin C occurs as the GFR falls and is often detectable before there is a measurable decrease in kidney function (GFR). Because cystatin C levels fluctuate with changes in GFR, there has been interest in the CysC blood test as one method of evaluating kidney function. Tests currently used include creatinine, a byproduct of muscle metabolism that is measured in the blood and urine, blood urea nitrogen (BUN), and eGFR (an estimate of the GFR usually calculated from the blood creatinine level). Unlike creatinine, cystatin C is not significantly affected by muscle mass (hence, sex or age), race, or diet, which has led to the idea that it could be a more reliable marker of kidney function and potentially used to generate a more precise estimate of GFR. While there are growing data and literature supporting the use of cystatin C, there is still a degree of uncertainty about when and how it should be used. However, testing is becoming increasingly more available and steps are being taken toward standardizing the calibration of cystatin C results.

About GDU